NASDAQ: CGCCanopy Growth Corp Stock
$1.39+0.05 (+3.73%)
Updated Apr 29, 2025
CGC Price
$1.39
Fair Value Price
N/A
Market Cap
$204.50M
52 Week Low
$0.77
52 Week High
$14.10
P/E
-0.41x
P/B
0.5x
P/S
1.57x
PEG
N/A
Dividend Yield
N/A
Revenue
$192.19M
Earnings
-$326.16M
Gross Margin
30.5%
Operating Margin
-167.76%
Profit Margin
-169.7%
Debt to Equity
0.97
Operating Cash Flow
-$107M
Beta
1.79
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CGC Overview
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CGC's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
CGC
Ranked#49 of 58
Ranked#49 of 58
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.75 | A | |
| $32.49 | A | |
| $27.00 | A |
Be the first to know about important CGC news, forecast changes, insider trades & much more!
CGC News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CGC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CGC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CGC is good value based on its book value relative to its share price (0.5x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.09x)
P/B vs Industry Valuation
CGC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CGC due diligence checks available for Premium users.
Valuation
CGC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.41x
Industry
21.8x
Market
29.19x
CGC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.5x
Industry
2.09x
CGC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CGC's financial health
Profit margin
Revenue
$51.9M
Net Income
-$84.7M
Profit Margin
-163%
CGC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CGC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$808.5M
Liabilities
$397.7M
Debt to equity
0.97
CGC's short-term assets ($236.86M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CGC's long-term liabilities ($330.37M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CGC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CGC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$18.7M
Investing
-$10.3M
Financing
-$20.9M
CGC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CGC vs Pharmaceutical Stocks
Canopy Growth Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.